439940-48-4

Basic information

• Product Name: (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-Dimethyl-17-((R)-1-methyl-3-trityloxy-propyl)-hexadecahydro-cyclopenta[a]phenanthrene-3,7,12-triol
• Synonyms: (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-Dimethyl-17-((R)-1-methyl-3-trityloxy-propyl)-hexadecahydro-cyclopenta[a]phenanthrene-3,7,12-triol
• CAS NO: 439940-48-4
• Molecular Weight: 622.888
• Mol File: 439940-48-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-Dimethyl-17-((R)-1-methyl-3-trityloxy-propyl)-hexadecahydro-cyclopenta[a]phenanthrene-3,7,12-triol(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-Dimethyl-17-((R)-1-methyl-3-trityloxy-propyl)-hexadecahydro-cyclopenta[a]phenanthrene-3,7,12-triol(439940-48-4)
• EPA Substance Registry System: (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-Dimethyl-17-((R)-1-methyl-3-trityloxy-propyl)-hexadecahydro-cyclopenta[a]phenanthrene-3,7,12-triol(439940-48-4)

Safety Data

• Hazardous Substances Data: 439940-48-4(Hazardous Substances Data)

Upstream product

• 222022-03-9 Acetic acid (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-7-acetoxy-3-hydroxy-17-((R)-3-hydroxy-1-methyl-propyl)-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-12-yl ester 
• 51102-05-7 3α,7α,12α-triacetoxy-24,24-diphenyl-5β-chol-23-ene 
• 76-83-5 trityl chloride 
• 133376-74-6 24-nor-5β-cholane-3α,7α,12α,23-tetrol 

Downstream Products

• 222022-05-1 3-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7-Bis-(3-hydroxy-propoxy)-10,13-dimethyl-17-((R)-1-methyl-3-trityloxy-propyl)-hexadecahydro-cyclopenta[a]phenanthren-12-yloxy]-propan-1-ol 
• 222022-04-0 (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Tris-allyloxy-10,13-dimethyl-17-((R)-1-methyl-3-trityloxy-propyl)-hexadecahydro-cyclopenta[a]phenanthrene 

Relevant articles and documents

Incremental conversion of outer-membrane permeabilizers into potent antibiotics for gram-negative bacteria

Cholic acid derivatives appended with amine groups have been prepared for use as permeabilizers of the outer membranes of Gram-negative bacteria. These compounds interact synergistically with antibiotics such as erythromycin and novobiocin to inhibit grow

Cationic Steroid Antimicrobial Compositions and Methods of Use

The invention provides methods for decreasing or inhibiting human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo, or an adverse side effect of human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

Cationic Steroid Microbial Compositions and Methods of Use

The invention relates to methods for decreasing or inhibiting influenza virus infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with influenza infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of influenza infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).